Journal List > J Stroke > v.24(1) > 1154123

TOOLS
Kunz, Sporns, Psychogios, Fiehler, Chapot, Dorn, Grams, Morotti, Musolino, Lee, Kemmling, Henkes, Nikoubashman, Wiesmann, Jensen-Kondering, Möhlenbruch, Schlamann, Marik, Schob, Wendl, Turowski, Götz, Kaiser, Dimitriadis, Gersing, Liebig, Ricke, Reidler, Wildgruber, Mönch, and for the Save ChildS Investigators: Cost-Effectiveness of Endovascular Thrombectomy in Childhood Stroke: An Analysis of the Save ChildS Study
Original Article

J Stroke 2022;24(1):138-147.

Published online: 31 January 2022

DOI: https://doi.org/10.5853/jos.2021.01606

Cost-Effectiveness of Endovascular Thrombectomy in Childhood Stroke: An Analysis of the Save ChildS Study

Wolfgang G. Kunza, *, Peter B. Spornsb, c, *, Marios N. Psychogiosb, Jens Fiehlerc, René Chapotd, Franziska Dorne, Astrid Gramsf, Andrea Morottig, Patricia Musolinoh, Sarah Leei, André Kemmlingj, Hans Henkesk, Omid Nikoubashmanl, Martin Wiesmannl, Ulf Jensen-Konderingm, Markus Möhlenbruchn, Marc Schlamanno, Wolfgang Marikp, Stefan Schobq, Christina Wendlr, Bernd Turowskis, Friedrich Götzt, Daniel Kaiseru, Konstantinos Dimitriadisv, Alexandra Gersingw, Thomas Liebigw, Jens Rickea, Paul Reidlera, Moritz Wildgrubera, †, Sebastian Möncha, †; for the Save ChildS Investigators

aDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany

bDepartment of Neuroradiology, Clinic for Radiology & Nuclear Medicine, University Hospital Basel, Switzerland

cDepartment of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

dDepartment of Neuroradiology, Alfried-Krupp Hospital, Essen, Germany

eDepartment of Neuroradiology, University Hospital Bonn, Bonn, Germany

fDepartment of Neuroradiology, Medical University of Innsbruck, Innsbruck, Austria

gNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

hDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

iDivision of Child Neurology, Department of Neurology, Stanford University, Stanford, CA, USA

jDepartment for Neuroradiology, University Hospital Marburg, Marburg, Germany

kDepartment of Neuroradiology, Klinikum Stuttgart, Stuttgart, Germany

lDepartment of Neuroradiology, Aachen University, Aachen, Germany

mDepartment of Radiology and Neuroradiology, University Hospital of Schleswig-Holstein, Kiel, Germany

nDepartment of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany

oDepartment of Neuroradiology, University Hospital of Cologne, Cologne, Germany

pDivision of Neuroradiology and Musculoskeletal Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria

qDepartment for Neuroradiology, University Hospital Leipzig, Leipzig, Germany

rDepartment of Radiology, University Hospital Regensburg, Regensburg, Germany

sInstitute of Neuroradiology, University Hospital Duesseldorf, Duesseldorf, Germany

tDepartment of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany

uDepartment of Neuroradiology, University Hospital Carl Gustav Carus, Dresden, Germany

vDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany

wInstitute of Diagnostic and Interventional Neuroradiology, University Hospital, LMU Munich, Munich, Germany

Correspondence: Wolfgang G. Kunz Department of Radiology, University Hospital, LMU Munich, Marchioninistr 15, 81377 Munich, Germany Tel: +49-89-4400-73630 Fax: +49-89-4400-78832 E-mail: wolfgang.kunz@med.lmu.de

* These authors contributed equally to the manuscript as first author.

† These authors contributed equally to the manuscript as last author.

Received 4 May 2021       Revised 21 September 2021       Accepted 23 September 2021

Copyright © 2022 Korean Stroke Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and Purpose

The Save ChildS Study demonstrated that endovascular thrombectomy (EVT) is a safe treatment option for pediatric stroke patients with large vessel occlusions (LVOs) with high recanalization rates. Our aim was to determine the long-term cost, health consequences and cost-effectiveness of EVT in this patient population.

Methods

In this retrospective study, a decision-analytic Markov model estimated lifetime costs and quality-adjusted life years (QALYs). Early outcome parameters were based on the entire Save ChildS Study to model the EVT group. As no randomized data exist, the Save ChildS patient subgroup with unsuccessful recanalization was used to model the standard of care group. For modeling of lifetime estimates, pediatric and adult input parameters were obtained from the current literature. The analysis was conducted in a United States setting applying healthcare and societal perspectives. Probabilistic sensitivity analyses were performed. The willingness-to-pay threshold was set to $100,000 per QALY.

Results

The model results yielded EVT as the dominant (cost-effective as well as cost-saving) strategy for pediatric stroke patients. The incremental effectiveness for the average age of 11.3 years at first stroke in the Save ChildS Study was determined as an additional 4.02 lifetime QALYs, with lifetime cost-savings that amounted to $169,982 from a healthcare perspective and $254,110 when applying a societal perspective. Acceptability rates for EVT were 96.60% and 96.66% for the healthcare and societal perspectives.

Conclusions

EVT for pediatric stroke patients with LVOs resulted in added QALY and reduced lifetime costs. Based on the available data in the Save ChildS Study, EVT is very likely to be a cost-effective treatment strategy for childhood stroke.

Keywords: Pediatrics, Stroke, Thrombectomy, Cost-benefit analysis

Introduction

Ischemic stroke ranks among the most cost-intensive diseases in all Western countries. Its currently estimated direct and indirect annual costs in the United States are $50 billion [1]. For patients with acute anterior circulation large vessel occlusions (LVO), randomized controlled trials (RCTs) established endovascular thrombectomy (EVT) as standard of care (SC) for adults [2]. The widespread adoption has been supported and accelerated by several economic analyses, demonstrating EVT to be long-term cost-saving for healthcare systems across many different countries [3-7].
Pediatric arterial ischemic stroke differs vastly from adult stroke in prevalence, etiology, risk factors, symptoms, and neurologic outcome [8]. The SC is largely based on supportive care. The evidence on efficacy and safety of intravenous thrombolysis remains scarce after the Thrombolysis in Pediatric Stroke (TIPS) trial was closed for lack of accrual [9,10]. In recent years, severe strokes in children with LVO are increasingly being treated with EVT in specialized centers [11]. The Save ChildS Study demonstrated that EVT is a safe and effective treatment option for pediatric stroke patients and that a favorable outcome similar to EVT in adults can be achieved [12].
Pediatric patients represent a demographic group with a low incidence of stroke yet suffer the longest consequences of potential disability. Pediatric stroke is thereby linked to substantial direct healthcare costs in the first year, yet few reports exist on the long-term care costs [13] Given the longer remaining lifespan in children, pediatric stroke also influences indirect costs, e.g., as a result of reduced lifetime productivity and need for informal care by next of kin [14].
Our study aim was to determine the long-term cost and health consequences as well as cost-effectiveness of EVT in this patient population.

Methods

Ethics statement

The present study complies with the principles of the Declaration of Helsinki (1964). The present study was approved by the Institutional Review Board, and the requirement for written informed consent was waived. All of our patient population was previously reported in the Save ChildS Study [12].

Model structure

A decision model using dedicated analytic software (TreeAge Pro 2021 version 21.1.0, TreeAge, Williamstown, MA, USA) was applied to evaluate the cost-effectiveness of EVT versus SC. Adhering to the recommendations by the Second Panel on Cost-Effectiveness in Health and Medicine [14]. We performed analyses adopting the healthcare as well as a societal perspective. A short-run model was created to analyze costs and functional outcomes within the initial 90 days after the index stroke. Pediatric stroke patients with LVO enter the model on admission to the hospital, receive either EVT or SC and afterwards enter one of the seven health states according to the degree of disability as assessed by the modified Rankin Scale (mRS).
A long-run Markov state transition model was used to estimate the expected costs and outcomes over the lifetime of the patient, using a cycle length of 1 year. During each cycle, patients could either remain in the same health state, experience a recurrent stroke and recover to the same mRS state or transit to a lower mRS state, or die from other causes. Absorbing states were death due to stroke or death due to any other cause. The model structure is shown in Figure 1.

Model input parameters

The input parameters for the model were based on the most recently published literature providing the best available level of evidence (Table 1) [2,7,15-37]. To study the impact of patient age, we based this study on a dedicated systematic and comprehensive literature review regarding age dependency of model input parameters [38].

Initial and transition probabilities

The initial probabilities (i.e., the probability of entering a specific mRS health state at hospital discharge) were based on outcomes in the Save ChildS Study [12]. This multicenter trial included 73 children from 27 participating stroke centers. There is no randomized data on the use of EVT versus SC in children. Following careful interdisciplinary discussion among the study coordinators, the best approach to model outcomes for the SC group was considered to be based on the Save ChildS study subgroup with unsuccessful recanalization (modified Thrombolysis in Cerebral Infarction [mTICI] 0–2a). The outcome parameters of the entire Save ChildS Study population were used to model the EVT group, i.e., any recanalization status (mTICI 0–3). The mRS outcomes for both subgroups are provided in Figure 2.
The transition probabilities consisted of the probability of staying in the same health state, the annual recurrent stroke rate, the probabilities of reentering the same or a lower health state following recurrent stroke, and the age-specific annual death rate. Based on several long-term follow-up studies on functional recovery after stroke, we assumed no significant mRS change in the long-term after stroke [15-17]. The pediatric recurrent stroke rate was obtained from a long-term follow-up study of childhood stroke [39]. The adult recurrent stroke rate is known to decrease over time after the index stroke and to increase with patient age; corresponding rates were available from a contemporary long-term study in adults [18]. Both aspects were built into the model. The age-specific annual death rate was drawn from the United States Life Table [19]. The death rate was adjusted according to adult hazard rate ratios for each of the mRS health states [20], which are considered to be age-independent [20]. The probabilities to reenter the health states following a recurrent stroke were approximated for both arms using age-dependent resampling of the initial probabilities of the Save ChildS Study and in case of adult recurrent stroke following the according age subgroup receiving SC in a meta-analysis on LVO in adult patients, a conservative assumption based on literature review [18,40-42].

Direct costs

Both direct acute and long-term costs were stratified for each of the seven health states (mRS levels 0–6). The acute treatment costs in the first 90 days were based on a study that determined the implied costs for each mRS score in adults [21]. The costs for EVT and SC were added to the acute treatment costs within 90 days according to the specific strategy. Based on studies that investigated the material usage, procedure times and recanalization rates, we assumed that the EVT procedure costs are independent of patient age [30,31].
The long-term annual treatment costs were based on contemporary data from the United States for each level of the mRS score [7]. In line with the literature, the acute and long-term costs were not adjusted for patient age [22-29]. All costs were converted to 2020 United States Dollars according to the medical care component of the Consumer Price Index [43] and discounted by 3% each year [14].

Indirect costs

To adopt a societal perspective, we assessed the indirect costs caused by childhood stroke based on the human capital approach. According to this approach, the amount of the productivity losses is measured based on (1) the lost productivity due to premature mortality in stroke patients; (2) the reduced productivity that is caused by the morbidity of stroke survivors; and (3) the costs for informal caregiving by next of kin [14].
To analyze the costs caused by premature mortality (1), we used age-dependent productivity measures based on nationwide average gross wages of the employed population. Gross wage data were available for citizens from 16 years up to 80 years of age by the United States Census Bureau (Current Population Survey) [44]. These productivity measures were combined with the general population employment status provided by the United States Bureau of Labor Statistics [45]. Non-stroke-related deaths were not considered for premature mortality.
To model the costs implied by the reduced productivity of stroke survivors (2), we multiplied the above-mentioned productivity measures by the relative earnings of stroke survivors compared to the non-stroke population (82.5%) [46]. To our knowledge, there is no data that represent the relative earnings depending on the functional disability as measured on the mRS scale. As there is consensus on the fact that the patient’s level of disability is the most important predictor of return-to-work (RTW) [47], we used the functional outcome as an alternative approach as previously described [47]. We multiplied each above-mentioned productivity measure by the RTW probability of stroke survivors, respective of their current level of disability and calculated the difference to the annual earnings of a healthy age-matched individual. We used reported RTW probabilities stratified by individual mRS health states (mRS 0, 0.63; mRS 1, 0.72; mRS 2, 0.49; mRS 3, 0.19; mRS 4, 0.14; mRS 5, 0.00) [48]. RTW was shown to be mainly influenced by the degree of disability than by patient age [49,50].
The annual costs for informal caregiving (3) were based on estimates for the United States [51] and stratified by degrees of disability (mRS 0–1 vs. mRS 2–5). The hourly wages for home health aides in the United States of the recently reported year 2018 were used to calculate annual costs. These additional input parameters to model the societal perspective are provided in Table 1.

Utilities

Therapy effectiveness was measured by quality-adjusted life years (QALYs), calculated by multiplying years spent in mRS health states by assigned utility weights. Utility weights were derived from a recent survey that used a patient-centered approach [33]. In line with several studies on health-related quality of life after ischemic stroke, patient age was assumed to have no significant influence on the utility weights [34-37]. Values range from 0.0 to 1.0, with 0.0 representing no, and 1.0 representing perfect quality of life. All QALYs were discounted by 3% each year [14].

Cost-effectiveness analysis

Treatment strategies were compared in terms of incremental costs, incremental effectiveness and incremental cost-effectiveness ratios. In line with recent recommendations [14,52], we applied different willingness-to-pay (WTP) thresholds ($50,000, $100,000, and $150,000 per QALY). Cost-effectiveness acceptability rates were determined for different patient ages.

Sensitivity analysis

To test the robustness of the model, we conducted probabilistic sensitivity analyses, allowing for simultaneous alteration of multiple model input parameters. The starting age was set to the median age in the Save ChildS Study of 11.3 years. Distribution types were used according to probability density functions for 2nd order Monte Carlo simulation runs (n=10,000). The distribution type for the model input parameters is shown in Table 1. To study the impact of the pediatric recurrent stroke rate in the first year after index stroke, deterministic one-way sensitivity analysis was performed.

Results

Probabilistic sensitivity analyses

The model results yielded EVT as the dominant (i.e., cost-effective as well as cost-saving) strategy for pediatric stroke patients. The median cumulative effectiveness over the lifetime was estimated with 20.33 QALYs for EVT treatment and 16.33 QALYs for SC treatment. The median lifetime healthcare costs amounted to $559,212 for EVT treatment and to $729,195 for SC treatment. The incremental effectiveness for the average age of 11.3 years at first stroke in the Save ChildS Study was thus determined as an additional 4.02 lifetime QALYs, with lifetime cost-savings that amounted to $169,982 from a healthcare perspective and $254,110 when applying a societal perspective.
Acceptability rates for EVT were consistently higher than 95% for all tested WTP thresholds and for both perspectives. EVT reached 96.49% and 96.64% acceptability at a WTP of $100,000/QALY for the healthcare and societal perspectives. The detailed results are presented in Table 2. Cost-effectiveness planes showing scatter plots of incremental costs and effectiveness of the 10,000 simulation runs are presented in Figure 3.

One-way sensitivity analysis of pediatric recurrent stroke rate

The deterministic one-way sensitivity analysis for first-year recurrent stroke rate yielded cost-effectiveness for EVT even up to a rate of 50%. The lifetime costs remained lower with EVT across the range from 0% to 50% (Figure 4A), while incremental QALYs continually declined as a result of the shortened life expectancy (Figure 4B). Incremental net monetary benefit values remained positive across the range from 0% up to 50% first-year recurrent stroke rate (Figure 4C).

Discussion

Our study systematically investigated the cost-effectiveness of EVT for pediatric patients with LVO stroke. Adopting a United States healthcare as well as a societal perspective, EVT was the dominant strategy, resulting in significant lifetime health benefits and cost-savings compared with conventional SC management. From an economic point of view, there is clear support for EVT as the preferred treatment strategy in this patient population.
While several large prospective randomized trials have shown the clear benefit of EVT in adulthood stroke, making it the SC in acute LVO, only small cohorts have been published investigating the use of EVT in childhood stroke [11,53]. The Save ChildS study was the first multicenter retrospective analysis of the use of EVT for LVO in children, demonstrating technical and clinical success rates comparable to the large RCTs in adults, with a good safety profile. This holds even true for children with LVO presenting in the late therapeutic window of up to 24 hours after onset of symptoms and different age groups [54,55].
As prospective randomized trials on EVT in children will most likely never become available, the evidence level will be based on those retrospective cohorts as well as prospective registry data. Even though there are several borderline indications such as underlying arteriopathies [56], in light of the moderate evidence of intravenous thrombolysis in pediatric LVO [9,10], EVT is increasingly advocated in the pediatric stroke community [57,58].
The major strength of this analysis is a detailed literature re- view regarding age dependency of model input parameters and the modification during the pediatric and adult timeline during the lifetime simulations as well as data access to the largest contemporary cohort on pediatric EVT. Moreover, this study included a healthcare as well as a societal perspective, as currently recommended by the Second Panel on Cost-Effectiveness in Health and Medicine [14].
There are several limitations of our study that need to be taken into account when interpreting the results. First, the study design was retrospective with the inherent limitations of this type of design, for example regarding model input data or change in procedure over time of recruitment. Second, outcomes for EVT and SC had to be modeled based on successful and futile recanalization as no randomized data or respective SC cohort data were available. As the complication rate of EVT is also very low in children, this approach may best model the differences in outcome and has been used before to study EVT treatment effects in large core strokes in adults [59]. Third, it was not feasible to study different pediatric age subgroups based on the limited patient numbers. Fourth, several of the cost input parameters had to be modelled on the basis of adult data as there were no corresponding pediatric data available in the literature. Fifth, mRS was applied as the outcome parameter that defined the different health states. This was also due to a paucity of data on pediatric stroke outcome measures regarding modeling of quality of life and direct as well as indirect costs. Sixth, due to the lack of data for childhood stroke we had to assume that the RTW after stroke was mainly influenced by the mRS outcome, which was only available from a small cohort and had limited data for the mRS 0 subgroup. No data was available to model RTW changes during the process of aging.

Conclusions

In conclusion, our analysis of EVT based on the Save ChildS Study resulted in added QALYs and reduced lifetime costs. Based on the available data, EVT is very likely to be a cost-effective and cost-saving treatment strategy for childhood stroke.

Notes

Disclosure

Jens Fiehler reported serving as a paid consultant for Acandis, Boehringer Ingelheim, Cerenovus, Covidien, Evasc Neurovascular, MD Clinicals, Medtronic, Medina, Microvention, Penumbra, Route92, Stryker, and Transverse Medical. Jens Fiehler is also CEO of Eppdata. Dr Chapot reported receiving personal fees from Microvention, Stryker, Medtronic, Balt, Siemens, and Rapid Medical outside the submitted work. Franziska Dorn received personal fees for consultancy from Acandis, Phenox, Balt, and Cerenovus. Hans Henkes reported receiving personal fees and nonfinancial support from Phenox GmbH during the conduct of the study; in addition, Hans Henkes had patents issued to 10 2004 040 868.8, 200580033578.6, 11/ 678,285, 50 2006 012 111.5, PCT/EP 2005/ 009057, 05 777 177.6-2318, and 10 2005 059 670.3, and is coinventor of several other patents related to thrombectomy. Martin Wiesmann reported receiving grants, personal fees, and nonfinancial support from Stryker Neurovascular; personal fees and nonfinancial support from Medtronic, Penumbra Inc, and Siemens Healthcare; and nonfinancial support from ab medica, Acandis, Asahi Intecc, Cerenovus, Kaneka Pharmaceuticals, Mentice AB, Microvention, and Phenox outside the submitted work. Markus Möhlenbruch reported receiving grants and nonfinancial support from Balt; personal fees from Medtronic; grants, personal fees, and nonfinancial support from MicroVention; and grants and personal fees from Stryker outside the submitted work. Alexander Radbruch reported receiving grants and personal fees from Guerbet and Bayer outside the submitted work. André Kemmling reported receiving personal fees from Penumbra, Stryker, and Phenox outside the submitted work. No industry support of the project was obtained.

References

1. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics: 2021 update: a report from the American Heart Association. Circulation. 2021; 143:e254–e743.
2. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016; 387:1723–1731.
crossref
3. Leppert MH, Campbell JD, Simpson JR, Burke JF. Cost-effectiveness of intra-arterial treatment as an adjunct to intravenous tissue-type plasminogen activator for acute ischemic stroke. Stroke. 2015; 46:1870–1876.
crossref
4. Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K. Cost-utility analysis of mechanical thrombectomy using stent retrievers in acute ischemic stroke. Stroke. 2015; 46:2591–2598.
crossref
5. Aronsson M, Persson J, Blomstrand C, Wester P, Levin LÅ. Cost-effectiveness of endovascular thrombectomy in patients with acute ischemic stroke. Neurology. 2016; 86:1053–1059.
crossref
6. Kunz WG, Hunink MG, Sommer WH, Beyer SE, Meinel FG, Dorn F, et al. Cost-effectiveness of endovascular stroke therapy: a patient subgroup analysis from a US healthcare perspective. Stroke. 2016; 47:2797–2804.
7. Shireman TI, Wang K, Saver JL, Goyal M, Bonafé A, Diener HC, et al. Cost-effectiveness of solitaire stent retriever thrombectomy for acute ischemic stroke: results from the SWIFT-PRIME trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). Stroke. 2017; 48:379–387.
8. Jordan LC, Hillis AE. Challenges in the diagnosis and treatment of pediatric stroke. Nat Rev Neurol. 2011; 7:199–208.
crossref
9. Rivkin MJ, deVeber G, Ichord RN, Kirton A, Chan AK, Hovinga CA, et al. Thrombolysis in pediatric stroke study. Stroke. 2015; 46:880–885.
crossref
10. Amlie-Lefond C, Shaw DW, Cooper A, Wainwright MS, Kirton A, Felling RJ, et al. Risk of intracranial hemorrhage following intravenous tPA (tissue-type plasminogen activator) for acute stroke is low in children. Stroke. 2020; 51:542–548.
crossref
11. Sporns PB, Kemmling A, Hanning U, Minnerup J, Sträter R, Niederstadt T, et al. Thrombectomy in Childhood Stroke. J Am Heart Assoc. 2019; 8:e011335.
crossref
12. Sporns PB, Sträter R, Minnerup J, Wiendl H, Hanning U, Chapot R, et al. Feasibility, safety, and outcome of endovascular recanalization in childhood stroke: the Save ChildS Study. JAMA Neurol. 2020; 77:25–34.
crossref
13. Ellis C, McGrattan K, Mauldin P, Ovbiagele B. Costs of pediatric stroke care in the United States: a systematic and contemporary review. Expert Rev Pharmacoecon Outcomes Res. 2014; 14:643–650.
crossref
14. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016; 316:1093–1103.
15. Luengo-Fernandez R, Paul NL, Gray AM, Pendlebury ST, Bull LM, Welch SJ, et al. Population-based study of disability and institutionalization after transient ischemic attack and stroke: 10-year results of the Oxford Vascular Study. Stroke. 2013; 44:2854–2861.
16. Wolfe CD, Crichton SL, Heuschmann PU, McKevitt CJ, Toschke AM, Grieve AP, et al. Estimates of outcomes up to ten years after stroke: analysis from the prospective South London Stroke Register. PLoS Med. 2011; 8:e1001033.
crossref
17. Ganesh A, Luengo-Fernandez R, Wharton RM, Gutnikov SA, Silver LE, Mehta Z, et al. Time course of evolution of disability and cause-specific mortality after ischemic stroke: implications for trial design. J Am Heart Assoc. 2017; 6:e005788.
crossref
18. Pennlert J, Eriksson M, Carlberg B, Wiklund PG. Long-term risk and predictors of recurrent stroke beyond the acute phase. Stroke. 2014; 45:1839–1841.
crossref
19. Arias E, Xu J. United States life tables, 2018. Natl Vital Stat Rep. 2020; 69:1–45.
20. Slot KB, Berge E, Sandercock P, Lewis SC, Dorman P, Dennis M, et al. Causes of death by level of dependency at 6 months after ischemic stroke in 3 large cohorts. Stroke. 2009; 40:1585–1589.
crossref
21. Dawson J, Lees JS, Chang TP, Walters MR, Ali M, Davis SM, et al. Association between disability measures and healthcare costs after initial treatment for acute stroke. Stroke. 2007; 38:1893–1898.
crossref
22. Caro JJ, Huybrechts KF, Duchesne I. Management patterns and costs of acute ischemic stroke: an international study. For the Stroke Economic Analysis Group. Stroke. 2000; 31:582–590.
23. Caro JJ, Huybrechts KF, Kelley HE. Predicting treatment costs after acute ischemic stroke on the basis of patient characteristics at presentation and early dysfunction. Stroke. 2001; 32:100–106.
crossref
24. Luengo-Fernandez R, Gray AM, Rothwell PM. Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke. 2006; 37:2579–2587.
crossref
25. Luengo-Fernandez R, Gray AM, Rothwell PM. Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison. Lancet Neurol. 2009; 8:235–243.
crossref
26. Yoneda Y, Uehara T, Yamasaki H, Kita Y, Tabuchi M, Mori E. Hospital-based study of the care and cost of acute ischemic stroke in Japan. Stroke. 2003; 34:718–724.
crossref
27. Diringer MN, Edwards DF, Mattson DT, Akins PT, Sheedy CW, Hsu CY, et al. Predictors of acute hospital costs for treatment of ischemic stroke in an academic center. Stroke. 1999; 30:724–728.
crossref
28. Alvarez-Sabín J, Quintana M, Masjuan J, Oliva-Moreno J, Mar J, Gonzalez-Rojas N, et al. Economic impact of patients admitted to stroke units in Spain. Eur J Health Econ. 2017; 18:449–458.
crossref
29. Holloway RG, Witter DM Jr, Lawton KB, Lipscomb J, Samsa G. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996; 46:854–860.
30. Castonguay AC, Zaidat OO, Novakovic R, Nguyen TN, Taqi MA, Gupta R, et al. Influence of age on clinical and revascularization outcomes in the North American Solitaire Stent-Retriever Acute Stroke Registry. Stroke. 2014; 45:3631–3636.
31. Beumer D, Rozeman AD, Lycklama À Nijeholt GJ, Brouwer PA, Jenniskens SF, Algra A, et al. The effect of age on outcome after intra-arterial treatment in acute ischemic stroke: a MR CLEAN pretrial study. BMC Neurol. 2016; 16:68.
crossref
32. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health. 2002; 5:82–97.
crossref
33. Chaisinanunkul N, Adeoye O, Lewis RJ, Grotta JC, Broderick J, Jovin TG, et al. Adopting a patient-centered approach to primary outcome analysis of acute stroke trials using a utilityweighted modified Rankin scale. Stroke. 2015; 46:2238–2243.
crossref
34. Hallan S, Asberg A, Indredavik B, Widerøe TE. Quality of life after cerebrovascular stroke: a systematic study of patients’ preferences for different functional outcomes. J Intern Med. 1999; 246:309–316.
crossref
35. Gargano JW, Reeves MJ; Paul Coverdell National Acute Stroke Registry Michigan Prototype Investigators. Sex differences in stroke recovery and stroke-specific quality of life: results from a statewide stroke registry. Stroke. 2007; 38:2541–2548.
36. Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, et al. Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke. 2006; 37:2567–2572.
crossref
37. Naess H, Waje-Andreassen U, Thomassen L, Nyland H, Myhr KM. Health-related quality of life among young adults with ischemic stroke on long-term follow-up. Stroke. 2006; 37:1232–1236.
crossref
38. Kunz WG, Hunink MG, Dimitriadis K, Huber T, Dorn F, Meinel FG, et al. Cost-effectiveness of endovascular therapy for acute ischemic stroke: a systematic review of the impact of patient age. Radiology. 2018; 288:518–526.
39. Sträter R, Becker S, von Eckardstein A, Heinecke A, Gutsche S, Junker R, et al. Prospective assessment of risk factors for recurrent stroke during childhood: a 5-year follow-up study. Lancet. 2002; 360:1540–1545.
40. Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD, et al. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke. 2003; 34:1457–1463.
41. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke. 2004; 35:731–735.
crossref
42. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011; 42:1489–1494.
43. Consumer Price Index. U.S. Bureau of Labor Statistics. http://www.bls.gov/cpi. 2020. Accessed October 28, 2021.
44. Current population survey. United States Census Bureau. https://www.census.gov/cps/data/cpstablecreator.html. 2019. Accessed October 28, 2021.
45. Household data annual averages: 3. employment status of the civilian noninstitutional population by age, sex, and race. U.S. Bureau of Labor Statistics. https://www.bls.gov/cps/cpsaat03.pdf. 2020. Accessed October 28, 2021.
46. Vyas MV, Hackam DG, Silver FL, Laporte A, Kapral MK. Lost productivity in stroke survivors: an econometrics analysis. Neuroepidemiology. 2016; 47:164–170.
crossref
47. Brown DL, Boden-Albala B, Langa KM, Lisabeth LD, Fair M, Smith MA, et al. Projected costs of ischemic stroke in the United States. Neurology. 2006; 67:1390–1395.
crossref
48. Tanaka H, Toyonaga T, Hashimoto H. Functional and occupational characteristics predictive of a return to work within 18 months after stroke in Japan: implications for rehabilitation. Int Arch Occup Environ Health. 2014; 87:445–453.
crossref
49. Saeki S, Ogata H, Okubo T, Takahashi K, Hoshuyama T. Factors influencing return to work after stroke in Japan. Stroke. 1993; 24:1182–1185.
crossref
50. Ferro JM, Crespo M. Prognosis after transient ischemic attack and ischemic stroke in young adults. Stroke. 1994; 25:1611–1616.
crossref
51. Hickenbottom SL, Fendrick AM, Kutcher JS, Kabeto MU, Katz SJ, Langa KM. A national study of the quantity and cost of informal caregiving for the elderly with stroke. Neurology. 2002; 58:1754–1759.
crossref
52. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014; 371:796–797.
53. Bigi S, Dulcey A, Gralla J, Bernasconi C, Melliger A, Datta AN, et al. Feasibility, safety, and outcome of recanalization treatment in childhood stroke. Ann Neurol. 2018; 83:1125–1132.
crossref
54. Sporns PB, Psychogios MN, Straeter R, Hanning U, Minnerup J, Chapot R, et al. Clinical diffusion mismatch to select pediatric patients for embolectomy 6 to 24 hours after stroke: an analysis of the Save ChildS Study. Neurology. 2021; 96:e343–e351.
55. Sporns PB, Straeter R, Minnerup J, Wiendl H, Hanning U, Chapot R, et al. Does device selection impact recanalization rate and neurological outcome?: an analysis of the Save ChildS Study. Stroke. 2020; 51:1182–1189.
56. Sun LR, Harrar D, Drocton G, Castillo-Pinto C, Felling R, Carpenter JL, et al. Mechanical thrombectomy for acute ischemic stroke: considerations in children. Stroke. 2020; 51:3174–3181.
57. Chabrier S, Ozanne A, Naggara O, Boulouis G, Husson B, Kossorotoff M. Hyperacute recanalization strategies and childhood stroke in the evidence age. Stroke. 2021; 52:381–384.
crossref
58. Sporns PB, Psychogios M. Thrombectomy in childhood stroke: important considerations in borderline indications. Stroke. 2020; 51:2890–2891.
59. Broocks G, Hanning U, Flottmann F, Schönfeld M, Faizy TD, Sporns P, et al. Clinical benefit of thrombectomy in stroke patients with low ASPECTS is mediated by oedema reduction. Brain. 2019; 142:1399–1407.
crossref

Figure 1.
Model structure. mRS, modified Rankin Scale.
jos-2021-01606f1.tif
Figure 2.
Save ChildS Study outcomes by recanalization grade. Pediatric stroke outcomes on the modified Rankin Scale during hospital discharge stratified by modified Thrombolysis in Cerebral Infarction (mTICI) scores. The mTICI 0–3 group represents all patients in the Save ChildS study and was used to model outcomes of the thrombectomy group. The mTICI 0–2a group represents patients with unsuccessful recanalization; these outcomes were used to model the standard of care group.
jos-2021-01606f2.tif
Figure 3.
Probabilistic sensitivity analysis from the healthcare and societal perspective. Cost-effectiveness planes of incremental costs and incremental effectiveness of endovascular thrombectomy (EVT) versus standard care are shown for the probabilistic sensitivity analysis. Each dot represents one simulation run. The dashed line indicates a willingness-to-pay threshold of $100,000/quality-adjusted life year (QALY). Dots right to this line are considered cost-effective simulation runs. Dots in the right lower quadrant indicate cost-savings combined with incremental QALYs by EVT.
jos-2021-01606f3.tif
Figure 4.
Sensitivity analysis of first-year pediatric recurrent stroke rate. Deterministic one-way sensitivity analysis results are shown for the societal perspective, including societal lifetime costs (A), lifetime quality-adjusted life years (QALYs) (B), and incremental net monetary benefit for endovascular thrombectomy (EVT) compared with standard care (SC) (C). Positive incremental net monetary benefit values indicate cost-effectiveness of EVT based on a willingness-to-pay of $100,000/QALY.
jos-2021-01606f4.tif
Table 1.
Base-case values and sources of model input parameters
Model input Base-case value* Distribution Source
Initial probabilities
  For each health state mRS 0–6 of EVT-treated patients Discharge mRS distribution for mTICI 0–3 recanalization Dirichlet Save ChildS Study Sporns et al. [12] (Figure 2)
For each health state mRS 0–6 of SC-treated patients Discharge mRS distribution for mTICI 0–2a recanalization Dirichlet Save ChildS Study Sporns et al. [12] (Figure 2)
Treatment with IVT 0.219 β Save ChildS Study Sporns et al. [12]
Transition probabilities
Pediatric recurrent stroke rate 0.066 (over first 5 years) β Sträter et al. [39]
Adult recurrent stroke rate Based on cycle age and time since index stroke β Pennlert et al. [18]
Annual death rate 0.000103 (for 11 years old) β US Life Table 2017 [44]
Annual death hazard rates for survivors mRS 0/1/2/3/4/5 1.53/1.52/2.17/3.18/4.55/6.55 Log normal Kunz et al. [38]
After recurrent pediatric stroke Discharge mRS distribution for mTICI 0–2a recanalization Dirichlet Save ChildS Study Sporns et al. [12]
After recurrent adult stroke 90-day mRS control arm Dirichlet HERMES Goyal et al. [2]
Health care costs
Costs within first 90 days after stroke for mRS 0/1/2/3/4/5/6 (excluding IVT and EVT) $8,778/$12,117/$19,031/$23,536/$31,537/$37,674/$8,856 ɣ Dawson et al. [21]
Additional cost of IVT treatment $7,641 ɣ NIS 2018 [43]
Additional cost of EVT treatment $15,977 ɣ Shireman et al. [7]
Long-term annual costs after stroke for mRS 0/1/2/3/4/5 $12,344/$12,711/$14,704/$25,258/$51,104/$75,131 ɣ Shireman et al. [7]
Recurrent stroke hospitalization $25,283 ɣ Chambers et al. [32]
Utilities
mRS 0/1/2/3/4/5/6 1.00/0.91/0.76/0.65/0.33/0.00/0.00 β Chaisinanunkul et al. [33]
Societal costs
Paid workforce productivity
Average annual earnings of employed population $13,441 (for 18 to 24 years old) ɣ US Census Bureau 2018
Population employment rate 0.400 (for 18 to 19 years old) β US Bureau of Labor Statistics 2020
Relative earnings of stroke survivors 0.825 β Vyas et al. [46]
Return-to-work after stroke mRS 0/1/2/3/4/5 0.63/0.72/0.49/0.19/0.14/0.00 β Tanaka et al. [48]
Unpaid domestic productivity
Informal annual caregiving costs mRS 0–1: $1,650 ɣ Hickenbottom et al. [51]
mRS 2–5: $8,253

All costs were converted to 2020 USD using the medical care component of the Consumer Price Index.

mRS modified Rankin Scale; EVT, endovascular thrombectomy; mTICI, modified Thrombolysis in Cerebral Infarction; IVT, intravenous thrombolysis; HERMES, Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials; NIS, National Inpatient Sample.

* The minimum and maximum values for ranges were derived from reported 95% confidence intervals or from calculated 95% confidence intervals with the use of variance estimates as available.

Table 2.
Results of probabilistic sensitivity analyses
Variable Healthcare perspective Societal perspective
EVT strategy
 Lifetime effectiveness 20.32 QALYs 20.34 QALYs
 Lifetime costs $559,212 $888,782
 Lifetime NMB* $455,029 $125,627
SC strategy
 Lifetime effectiveness 16.33 QALYs 16.32 QALYs
 Lifetime costs $729,195 $1,142,892
 Lifetime NMB* $85,219 -$326,351
EVT compared to SC strategy
 Incremental effectiveness 3.99 QALYs 4.02 QALYs
 Incremental costs –$169,982 –$254,110
 Incremental NMB* $369,810 $451,978
EVT acceptability at WTP
 $50,000/QALY 96.08% 96.61%
 $100,000/QALY 96.49% 96.64%
 $150,000/QALY 96.60% 96.66%

All values are median values derived from probabilistic sensitivity analyses using 10,000 second order Monte Carlo simulation runs.

EVT, endovascular thrombectomy; QALY, quality-adjusted life year; NMB, net monetary benefit; SC, standard of care; WTP, willingness-to-pay.

* The WTP threshold was set to $100,000/QALY for all NMB calculations. Negative incremental costs indicate cost-savings and positive incremental NMB values represent higher net monetary benefits associated with EVT.

TOOLS
Similar articles